Zentalis Pharmaceuticals, Inc.
- ZNTL
- NASDAQ
- Biotechnology
- Oncology Therapeutics
- Small Molecule Drugs
$2.30
Today +7.98%Quote Oct 19, 2026, 08:00 PM UTC
−26.05%over the last month
Max drawdown −31.5%From 1-month high −26.0%3 months −54.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
106
Market value
$163.7M
Quote Oct 19
Floor
$2.29
0.4% below price
Resistance
$2.48
7.8% above price
Price vs analyst targets
12 analysts
Lowest target
$5.00Highest target
$10.00
$5.00Highest target
$10.00
- Price $2.30
- Average target $7.67
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 233% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ZNTLPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free